Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis

Neurology

Volumn 52, Issue 3, 1999, Pages 629-632

  Qureshi, Adnan I ^a,e   Choudhry, M A ^b   Akbar, M S ^c   Mohammad, Y ^c   Chua, H C ^a   Yahia, A M ^d   Ulatowski, J A ^a   Krendel, D A ^c   Leshner, R T ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOTHERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYASTHENIA; OBSERVER VARIATION; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033051085     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.3.629     Document Type: Article

References (9)

1. Bergamini L, Cocito D, Durelli L, Quattrololo G. Opinions about plasma exchange and associated treatments in the therapy of myasthenia gravis. Muscle Nerve 1983;6:457-458.
2. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48:1253-1260.
3. Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997;25:1228-1235.
4. Arsura R. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989;53: S170-S179.
5. Crunch Software Corporation. Crunch 4.0 Statistical Software. Oakland, CA: Crunch Software Corporation, 1991.
6. Dean AG, Dean AJ, Coulombier D, et al. Epi Info 6: a word processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta, GA: Centers for Disease Control and Prevention, 1995.
7. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.
8. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-796.
9. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis: response to plasmapharesis following failure of intravenous y-globulin. Arch Neurol 1993;50:837-840.